What happened
The US Commerce Department listed India among 20 jurisdictions eligible for a 0% tariff on certain specialty pharmaceutical products and ingredients, even as the US moves a 100% Section 232 tariff on specified licensed pharma products. Covered categories include orphan/rare-disease drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates (ADCs), some CBRN-threat medicines, and animal medicines. Generics remain outside the Section 232 pharma tariffs for now — important because generics dominate India’s US-bound drug exports.
Background
India exported drugs and pharmaceuticals worth about $30.46 billion in 2024-25 (Pharmexcil), with the US a major market. The waiver can apply where a trade/security agreement exists or is expected, or where Commerce finds an urgent US health need. Companies may seek case-by-case relief with product and medical-need details.
Why it matters for exams
- India–US trade and pharma exports are GS-II/III and banking current affairs
- Section 232 and orphan-drug definitions appear in economy notes
- Generic vs specialty distinction is exam-relevant
Key facts for exams
- Waiver: 0% tariff on listed specialty drugs/ingredients for 20 jurisdictions including India
- Parallel measure: 100% Section 232 tariff on certain licensed pharma products
- Generics: Currently not under those Section 232 pharma tariffs
- India pharma exports 2024-25: ~$30.46 billion (Pharmexcil)
- Examples covered: Orphan drugs, ADCs, cell/gene therapies, plasma therapies
Practice MCQs
Q1. Section 232 pharmaceutical tariffs of 100% currently do not apply to:
- Orphan drugs
- ADCs
- Generic pharmaceuticals
- Plasma therapies
Answer: C. Generics and associated ingredients are currently excluded.
Q2. India’s pharma exports in 2024-25 were about:
- $10 bn
- $20 bn
- $30.46 bn
- $50 bn
Answer: C. About $30.46 billion per Pharmexcil.
Q3. ADC in this context stands for:
- Advanced Drug Certificate
- Antibody-Drug Conjugate
- Ayush Drug Council
- Active Dose Capsule
Answer: B. Antibody-drug conjugates.
Source: The Indian Express / PTI (29 Sep 2026).